Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis

Abstract

A 43-year-old patient developed factor V inhibitor 6 months after liver transplantation for primary biliary cirrhosis in association with Sjögren's syndrome/systemic lupus erythematosus. She suffered from ecchymoses in the lower extremities. The factor V inhibitor was eradicated after 10 weekly doses of 375-500 mg/m2 rituximab. © 2004 Wiley-Liss, Inc.